🔎 Trials Near Me

Beranda › Karsinoma Sel Skuamosa Kepala dan Leher › Pennsylvania › Philadelphia

Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di Philadelphia, PA

25 studi untuk Karsinoma Sel Skuamosa Kepala dan Leher mencari peserta di lokasi sekitar Philadelphia (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

High-dose Prophylactic Gabapentin (HOPE) vs. Placebo to Prevent Opioid Use for Oral Mucositis Pain During Concurrent Chemoradiation for Head and Neck Cancer

Menerima pesertaFase 3
  • Thomas Jefferson University Hospital, Philadelphia
  • Jefferson Torresdale Hospital, Philadelphia
  • Asplundh Cancer Pavilion, Willow Grove · 13 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Okt 2026 · NCT06992427

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

Menerima pesertaFase 1
  • Exelixis Clinical Site #98, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT05176483

JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC

Menerima pesertaFase 3
  • University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
Usia 60 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT04892173

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Menerima pesertaFase 3
  • University of Pennsylvania Perelman Center for Advanced Medicine, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07276399

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 1
  • University of Pennsylvania, Philadelphia
Usia 18 hingga 74 · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT07219212

Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • Thomas Jefferson University Hospital, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
  • Jefferson Torresdale Hospital, Philadelphia
Usia 18 hingga 79 · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT04671667

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

Menerima pesertaFase 2
  • Fox Chase Cancer Center, Philadelphia
  • Temple University Hospital, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT02734537

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Menerima pesertaStudi observasional
  • University of Pennsylvania, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 14 Sep 2026 · NCT05059444

Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors

Menerima pesertaFase 2
  • Research Site, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT06535607

A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)

Menerima pesertaStudi observasional
  • University of Pennsylvania, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Sep 2026 · NCT06163534

FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors

Menerima pesertaFase 1
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Sep 2026 · NCT07216105

A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 2
  • Asplundh Cancer Pavilion, Willow Grove · 13 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 21 Agu 2026 · NCT06769698

A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

Menerima pesertaFase 1
  • Normunity Investigational Site, Philadelphia
  • Normunity Investigational Site, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT07182149

Comparing Radiation Plus Cetuximab to Radiation Plus Chemotherapy in People With Head and Neck Cancer Who Cannot Receive Cisplatin

Menerima pesertaFase 3
  • Christiana Care Health System-Concord Health Center, Chadds Ford · 23 mi jauhnya
  • Christiana Care Health System-Wilmington Hospital, Wilmington · 25 mi jauhnya
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT07441681

Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer

Menerima pesertaFase 2/3
  • Thomas Jefferson University Hospital, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04333537

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Menerima pesertaFase 1/2
  • University of Pennsylvania, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 29 Jul 2026 · NCT03526835

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

Menerima pesertaFase 1
  • Perelman Center for Advanced Medicine /ID# 250188, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT04777994

A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 3
  • GSK Investigational Site, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 26 Mei 2026 · NCT06256588

Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery

Menerima pesertaFase 1
  • Abramson Cancer Center at University of Pennsylvania, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 12 Mei 2026 · NCT06747390

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Menerima pesertaFase 1
  • Fox Chase Cancer Center, Philadelphia
  • Temple University Hospital, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Apr 2026 · NCT07455032

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

Menerima pesertaFase 3
  • Fox Chase Cancer Center, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 9 Apr 2026 · NCT06064877

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

Menerima pesertaFase 1/2
  • University of Pennsylvania, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Feb 2026 · NCT07030257

Virtual Reality 3D-Surgery Modeling to Enhance Head and Neck Cancer Surgery Quality

Menerima peserta
  • Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Feb 2026 · NCT05031910

A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

Menerima pesertaFase 1
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
  • Fox Chase Cancer Center, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Feb 2026 · NCT06778863

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

Menerima pesertaFase 3
  • Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 15 Okt 2025 · NCT06699212

Uji klinis Karsinoma Sel Skuamosa Kepala dan Leher di kota lain

Studi lain di Philadelphia

Dari ClinicalTrials.gov, data diambil 7 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.